百健

最新新闻

• 评级变动
  RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $260
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 公司公告
  Tanxin Biogen: Legal Opinion of Grandall Law Firm (Guangzhou) on the Adjustment of the Grant Price under Tanxin Biogen Co., Ltd.\'s 2024 Restricted Stock Incentive Plan
  SZSI · 2026/4/25
• 公司公告
  Tanxin Biogen: Verification Opinion of CITIC Securities Co., Ltd. on the Delay of Certain Fund-Raising Investment Projects of Tanxin Biogen Co., Ltd.
  SZSI · 2026/3/21
• Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $255
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $256
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• UBS Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $270
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $245
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Bernstein Initiates Biogen(BIIB.US) With Buy Rating, Announces Target Price $236
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• AI Predicted Novartis' $30 Billion Drug Failure. Are Biogen and Takeda Next?
  TipRanks · 2026/10/7
• 公司公告
  Biogen | 3: Initial statement of beneficial ownership of securities- BIOGEN INC.
  SEC · 2026/4/7
• 评级变动
  Wells Fargo Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Wolfe Research Upgrades Biogen(BIIB.US) to Buy Rating, Announces Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Citi Maintains Biogen(BIIB.US) With Hold Rating, Raises Target Price to $215
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  Tanxin Biogen: Attestation Report by Huaxing Certified Public Accountants (Special General Partnership) on the Annual Custody, Management, and Use of Funds Raised by Tanxin Biogen Co., Ltd.
  SZSI · 2026/3/21
• 评级变动
  Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $241
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  BMO Capital Maintains Biogen(BIIB.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Stifel Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $242
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $245
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 公司公告
  Apellis Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- BIOGEN INC.
  SEC · 2026/4/7
• Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $256
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $215 to $255
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Raises Target Price to $210
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $215 to $256
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251
  Benzinga · 2026/7/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。